AzTrials
AzTrials

Reduced Physical ActivityNCT02971098

Mechanisms of Skeletal Muscle Insulin Resistance in Older Adults

A study testing Reduced activity in people with Reduced Physical Activity, run by University of Utah at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The over-65 population is not only increasing at an alarming rate, but because six out of 10 will be managing more than one chronic condition by 2030, they will make up a much greater proportion of hospitalizations than ever before. Read more about this study

Who is it for?
Ages 60 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Reduced Physical Activity
What is being tested?
Reduced activity
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteUnited States
Study dates
Sep 2016to 17 Dec 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age between 60-85 yrs
  • Ability to sign informed consent
  • Free-living, prior to admission

Who cannot join

  • The participant must not have participated in any previous research studies utilizing ionizing radiation (either radioisotopes or diagnostic x-rays) during the past 12 months in order to participate in this study. Cardiac abnormalities considered exclusionary by the study physician
  • Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, diabetes)
  • History of kidney disease or failure
  • Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, diabetes, hypercholesterolemia > 250 mg/dl, claudication or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal and pedal arteries)
  • Risk of deep vein thrombosis (DVT) including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb>18 g/dL) or thrombocytosis (platelets>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocysteinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombin III
  • Use of anticoagulant therapy (e.g., Coumadin, heparin)
Show all 20Show fewer
  • Elevated systolic pressure >150 or a diastolic blood pressure > 100
  • Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)
  • Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
  • Currently on a weight-loss diet or body mass index > 30 kg/m2
  • Recent anabolic or corticosteroids use (within 3 months)
  • History of stroke with motor disability
  • A recent history (<12 months) of GI bleed
  • Exercise training (>2 session of moderate to high intensity aerobic or resistance exercise/week)
  • History of liver disease
  • History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)
  • Prior history of Heparin-Induced Thrombocytopenia (HIT)
  • Any other condition or event considered exclusionary by the PI and faculty physician
  • An HbA1c value at or greater than 6.5%
  • Subjects may not participate if they have utilized ionizing radiation (either radioisotopes or diagnostic x-rays) during the past 12 months

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Utah

    Salt Lake City, Utah, 84108

Other trials in United States

About this study

Official title: Novel Molecular Mechanisms of Skeletal Muscle Insulin, Resistance if Physically Inactive Older Adults

The over-65 population is not only increasing at an alarming rate, but because six out of 10 will be managing more than one chronic condition by 2030, they will make up a much greater proportion of hospitalizations than ever before. Hospitalizations for disease, injury, and/or surgery in this group are likely to impair physical mobility and, therefore, the older adults capacity to be physically active both during hospitalization and beyond. The resulting sedentary lifestyle is likely to be accepted as the "new normal", ultimately increasing the risk of skeletal muscle and metabolic dysfunction (e.g. impaired glucose disposal, insulin resistance). These devastating outcomes are neither inevitable nor necessary if prevented with an appropriate mechanism-based intervention.

A novel mechanism that may contribute to physical inactivity-induced insulin resistance is accumulation of inflammation and ceramide within skeletal muscle. Of interest, increased skeletal muscle inflammation and ceramide has been tied to various metabolic disturbances such as diabetes and insulin resistance. However, it is currently unknown if skeletal muscle inflammation and ceramide are a key mechanism associated with insulin resistance due to physical inactivity in older adults.

Read the detailed description

The investigator team will recruit younger and older (N=8; 18-35y and 60-85 yrs) male and female adults recruited in the Salt Lake City area.

The investigator team will then schedule separate visits for Strength, Power and Physical Function and the separate visits for Lean Mass and OGTT measurements (see description below).

  1. Lean Mass, oral glucose tolerance test , Strength, Power, Exercise Testing and Physical Function Measurements. Lean mass assessment via dual-energy X-ray absorptiometry (DXA), ultra sound and peripheral quantitative computed tomography (pQCT) will be assessed in the center for clinical and translational sciences (CCTS) while knee extensor isometric strength, power and physical function testing will be conducted in the Skeletal muscle exercise research facility (SMERF) laboratory (520 Wakara Way). These endpoints will be considered secondary objectives to determine relationships with insulin sensitivity and muscle cell signaling events. These tests will occur within one week before the reduced activity experiment and will be repeated after completing the reduced activity period and after exercise training. For lean mass assessment, subjects will be tested in the morning after an overnight fast prior to the DXA scan. Isometric strength will be assessed in both legs with a maximal voluntary isometric contraction effort (at a 600 knee angle) developed by the knee extensors (quadriceps) and plantar/dorsi flexor muscles on a dynamometer. For lower extremity extension power testing a Nottingham power rig will be used. The following battery of functional performance tests will be used: Stair ascent/descent time, six-minute walk distance, 50 foot walk time, and the timed up and go test. All tests are tests that we frequently and safely perform in older individuals. Maximal oxygen consumption (exercise testing) will be measured by a metabolic cart during a graded maximal exercise test on a stationary cycle ergometer. This test will be performed in the CCTS under direct supervision of an exercise physiologist.
  2. Physical Activity Monitoring, Dietary Record. Subjects will be fitted with an ankle Step Activity Monitor in order to determine their daily level of physical activity over 7 days period preceding the reduced physical activity study. Additionally, a 3-day daily dietary record will be self-reported before this period. The participant will be properly instructed by a research team member on how to conduct this reporting and how to wear the ankle activity monitor.
  3. Insulin Clamp Study, Metabolic Rate and Muscle Biopsies. On a separate day, participants will arrive at the CCTS fasted in the morning on Day 1 and a euglycemic-hyperinsulinemic clamp study will be performed as we have done previously. The research team physician will oversee the clamp procedure as he is very experienced using this method. Metabolic rate will be determined 30 minutes before the initiation of the insulin infusion and 30 minutes at the end of the insulin infusion period. Metabolic rate will be determined using a indirect calorimeter housed at the CCTS. To do so, the participant will be fitted with a canopy hood. The participant with breathe normally for 30 minutes during the procedure. The canopy will be removed then the first muscle biopsy will occur. A vastus lateralis muscle biopsy will be sampled before and 3h after the clamp combined with periodic blood sampling for measure of fasting and insulin-stimulated insulin, glucose, muscle cell signaling endpoints, and specific ceramide species. Biopsies will occur on opposite legs. Muscle biopsies were be performed by trained CCTS nurses as we have done routinely in our bed rest studies in older adults. Muscle samples will then be flash-frozen in liquid nitrogen and stored for later analysis. After the clamp experiment, subjects will begin the reduced physical inactivity study which will take place at the participant home. On Day 14, the participant again will return to the CCTS following an overnight fast and the insulin clamp study will be repeated in order to make comparisons to the pre insulin clamp study (Day 1).
  4. Reduced Physical inactivity experiment. After completion of the first insulin clamp experiment (Day 1), subjects will adhere to 14-days of reduced physical activity at their home as has been conduced before. The goal will be for the participant to maintain no more than ~2000 steps/day as determined by a monitor that the subject will be able to see and record. The investigators will inform the participant that their normal diet should remain the same. As mentioned above, on day 7, the participant will return for a DXA scan, OGTT's and thigh muscle biopsies. Also mentioned above, on Day 14, after an overnight fast, a second insulin clamp study coupled with muscle biopsies will be conducted as detailed above in the CCTS. Lean mass, strength, power, and physical function measurements will be re-assessed on a later day following the reduced activity study.
Being tested
Reduced activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Reduced activityProcedure or surgery

    Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.

Study groups in NCT02971098
Study groupRoleWhat they receive
Reduced activityExperimentalparticipants will undergo a reduced physical activity period (75% step reduction) for two weeks.
Receives: Procedure: Reduced activity

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Steady state glucose infusion rate

    Glucose infusion rate will be determined by a hyperinsulinemic-euglycemic clamp

    Measured: percent change from baseline at 14 days

Secondary outcomes (1)
  1. lean mass

    lean mass will be determined by DXA scan

    Measured: percent change from baseline at 14 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2016 (estimated)
  2. Study startSep 2016
  3. Primary completion17 Dec 2019
  4. Study completion17 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
2 weeks of physical inactivity
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02971098
Sponsor's protocol ID
84354
Status last verified
Jun 2022
First submitted
15 Nov 2016
Last updated
22 Jun 2022
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Reduced activity in people with Reduced Physical Activity, run by University of Utah at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Steady state glucose infusion rate (time frame: percent change from baseline at 14 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in